Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
36.38
-0.16 (-0.44%)
At close: Dec 5, 2025, 4:00 PM EST
37.29
+0.91 (2.50%)
After-hours: Dec 5, 2025, 7:56 PM EST
Ultragenyx Pharmaceutical Stock Forecast
Stock Price Forecast
The 15 analysts with 12-month price forecasts for Ultragenyx Pharmaceutical stock have an average target of 85.2, with a low estimate of 34 and a high estimate of 140. The average target predicts an increase of 134.19% from the current stock price of 36.38.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Ultragenyx Pharmaceutical stock from 15 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 6 | 5 | 5 | 5 | 6 |
| Buy | 9 | 9 | 8 | 8 | 8 | 8 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15 | 16 | 14 | 14 | 14 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Maintains $81 → $50 | Buy | Maintains | $81 → $50 | +37.44% | Nov 24, 2025 |
| TD Cowen | TD Cowen | Strong Buy Maintains $86 → $75 | Strong Buy | Maintains | $86 → $75 | +106.16% | Nov 5, 2025 |
| Truist Securities | Truist Securities | Strong Buy Maintains $100 → $90 | Strong Buy | Maintains | $100 → $90 | +147.39% | Nov 5, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $80 | Strong Buy | Reiterates | $80 | +119.90% | Sep 9, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $105 | Buy | Reiterates | $105 | +188.62% | Sep 5, 2025 |
Financial Forecast
Revenue This Year
667.17M
from 560.23M
Increased by 19.09%
Revenue Next Year
804.71M
from 667.17M
Increased by 20.62%
EPS This Year
-5.87
from -6.29
EPS Next Year
-4.19
from -5.87
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 696.4M | 931.0M | ||||
| Avg | 667.2M | 804.7M | ||||
| Low | 618.4M | 661.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 24.3% | 39.6% | ||||
| Avg | 19.1% | 20.6% | ||||
| Low | 10.4% | -0.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -4.71 | -1.11 | ||||
| Avg | -5.87 | -4.19 | ||||
| Low | -7.60 | -6.56 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.